[1]
Lupi A, Rognoni A, Cavallino C, Secco GG, Reale D, Cossa G, Rosso R, Bongo AS, Cortese B, Angiolillo DJ, Jaffe AS, Porto I. Intracoronary vs intravenous bivalirudin bolus in ST-elevation myocardial infarction patients treated with primary angioplasty. European heart journal. Acute cardiovascular care. 2016 Sep:5(5):487-96. doi: 10.1177/2048872615594499. Epub 2015 Jul 10
[PubMed PMID: 26163529]
[2]
Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thrombosis and haemostasis. 2008 May:99(5):830-9. doi: 10.1160/TH07-10-0644. Epub
[PubMed PMID: 18449412]
[3]
Janjua T, Nussbaum E, Lowary J, Babbini V. Bivalirudin as a bridge for anticoagulation in high risk neurosurgical patients with active DVT or high risk of thrombosis. Neurocritical care. 2013 Jun:18(3):349-53. doi: 10.1007/s12028-013-9835-0. Epub
[PubMed PMID: 23568093]
[4]
Koster A, Dyke CM, Aldea G, Smedira NG, McCarthy HL 2nd, Aronson S, Hetzer R, Avery E, Spiess B, Lincoff AM. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. The Annals of thoracic surgery. 2007 Feb:83(2):572-7
[PubMed PMID: 17257990]
[5]
Berlioz B, Kaseer HS, Sanghavi DK, Guru PK. Bivalirudin resistance in a patient on veno-venous extracorporeal membrane oxygenation with a therapeutic response to argatroban. BMJ case reports. 2020 Jan 7:13(1):. doi: 10.1136/bcr-2019-232262. Epub 2020 Jan 7
[PubMed PMID: 31915185]
Level 3 (low-level) evidence
[6]
Writing Committee Members, Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, Bittl JA, Cohen MG, DiMaio JM, Don CW, Fremes SE, Gaudino MF, Goldberger ZD, Grant MC, Jaswal JB, Kurlansky PA, Mehran R, Metkus TS Jr, Nnacheta LC, Rao SV, Sellke FW, Sharma G, Yong CM, Zwischenberger BA. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2022 Jan 18:79(2):197-215. doi: 10.1016/j.jacc.2021.09.005. Epub 2021 Dec 9
[PubMed PMID: 34895951]
Level 1 (high-level) evidence
[7]
Cuker A, Arepally GM, Chong BH, Cines DB, Greinacher A, Gruel Y, Linkins LA, Rodner SB, Selleng S, Warkentin TE, Wex A, Mustafa RA, Morgan RL, Santesso N. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood advances. 2018 Nov 27:2(22):3360-3392. doi: 10.1182/bloodadvances.2018024489. Epub
[PubMed PMID: 30482768]
Level 3 (low-level) evidence
[8]
Coughlan JJ, Kastrati A. Bivalirudin in patients with ST-segment elevation myocardial infarction. Lancet (London, England). 2022 Nov 26:400(10366):1822-1823. doi: 10.1016/S0140-6736(22)02162-6. Epub 2022 Nov 6
[PubMed PMID: 36351460]
[9]
Netley J, Roy J, Greenlee J, Hart S, Todt M, Statz B. Bivalirudin Anticoagulation Dosing Protocol for Extracorporeal Membrane Oxygenation: A Retrospective Review. The journal of extra-corporeal technology. 2018 Sep:50(3):161-166
[PubMed PMID: 30250342]
Level 2 (mid-level) evidence
[10]
Carswell CI, Plosker GL. Bivalirudin: a review of its potential place in the management of acute coronary syndromes. Drugs. 2002:62(5):841-70
[PubMed PMID: 11929334]
[11]
Regling K, Callaghan MU, Rajpurkar M. Bivalirudin during thrombolysis with catheter-directed tPA in a heparin-refractory patient: A case report. Pediatric blood & cancer. 2020 Feb:67(2):e28094. doi: 10.1002/pbc.28094. Epub 2019 Nov 20
[PubMed PMID: 31749252]
Level 3 (low-level) evidence
[12]
Li Y, Liang Z, Qin L, Wang M, Wang X, Zhang H, Liu Y, Li Y, Jia Z, Liu L, Zhang H, Luo J, Dong S, Guo J, Zhu H, Li S, Zheng H, Liu L, Wu Y, Zhong Y, Qiu M, Han Y, Stone GW. Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial. Lancet (London, England). 2022 Nov 26:400(10366):1847-1857. doi: 10.1016/S0140-6736(22)01999-7. Epub 2022 Nov 6
[PubMed PMID: 36351459]
Level 1 (high-level) evidence
[13]
Weisel JW, Litvinov RI. Fibrin Formation, Structure and Properties. Sub-cellular biochemistry. 2017:82():405-456. doi: 10.1007/978-3-319-49674-0_13. Epub
[PubMed PMID: 28101869]
[14]
Weitz JI, Middeldorp S, Geerts W, Heit JA. Thrombophilia and new anticoagulant drugs. Hematology. American Society of Hematology. Education Program. 2004:():424-38
[PubMed PMID: 15561696]
[15]
Zhang D, Wang Z, Zhao X, Lu W, Gu J, Cui Y. Pharmacokinetics, pharmacodynamics, tolerability and safety of single doses of bivalirudin in healthy chinese subjects. Biological & pharmaceutical bulletin. 2011:34(12):1841-8
[PubMed PMID: 22130240]
[16]
Kołtowski Ł, Legutko J, Filipiak KJ, Dziewierz A, Bartuś S, Buszman P, Buszman P, Ciećwierz D, Dąbrowski M, Dobrzycki S, Gil R, Gorący J, Grygier M, Jaguszewski M, Kochman J, Kubica J, Kuliczkowki W, Lodziński P, Ochała A, Reczuch K, Witkowski A, Wojakowski W, Wójcik J, Dudek D. Bivalirudin use in acute coronary syndrome patients undergoing percutaneous coronary interventions in Poland: Clinical update from expert group of the Association on Cardiovascular Interventions of the Polish Cardiac Society. Cardiology journal. 2019:26(1):1-7. doi: 10.5603/CJ.2019.0029. Epub
[PubMed PMID: 30882184]
[17]
Van De Car DA, Rao SV, Ohman EM. Bivalirudin: a review of the pharmacology and clinical application. Expert review of cardiovascular therapy. 2010 Dec:8(12):1673-81. doi: 10.1586/erc.10.158. Epub
[PubMed PMID: 21108549]
[18]
Sciulli TM, Mauro VF. Pharmacology and clinical use of bivalirudin. The Annals of pharmacotherapy. 2002 Jun:36(6):1028-41
[PubMed PMID: 12022907]
[19]
Writing Committee Members, Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, Bittl JA, Cohen MG, DiMaio JM, Don CW, Fremes SE, Gaudino MF, Goldberger ZD, Grant MC, Jaswal JB, Kurlansky PA, Mehran R, Metkus TS Jr, Nnacheta LC, Rao SV, Sellke FW, Sharma G, Yong CM, Zwischenberger BA. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2022 Jan 18:79(2):e21-e129. doi: 10.1016/j.jacc.2021.09.006. Epub 2021 Dec 9
[PubMed PMID: 34895950]
Level 1 (high-level) evidence
[20]
European Society of Gynecology (ESG), Association for European Paediatric Cardiology (AEPC), German Society for Gender Medicine (DGesGM), Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, Ferreira R, Foidart JM, Gibbs JS, Gohlke-Baerwolf C, Gorenek B, Iung B, Kirby M, Maas AH, Morais J, Nihoyannopoulos P, Pieper PG, Presbitero P, Roos-Hesselink JW, Schaufelberger M, Seeland U, Torracca L, ESC Committee for Practice Guidelines. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). European heart journal. 2011 Dec:32(24):3147-97. doi: 10.1093/eurheartj/ehr218. Epub 2011 Aug 26
[PubMed PMID: 21873418]
Level 1 (high-level) evidence
[21]
Bates SM, Middeldorp S, Rodger M, James AH, Greer I. Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. Journal of thrombosis and thrombolysis. 2016 Jan:41(1):92-128. doi: 10.1007/s11239-015-1309-0. Epub
[PubMed PMID: 26780741]
[23]
Forbes TJ, Hijazi ZM, Young G, Ringewald JM, Aquino PM, Vincent RN, Qureshi AM, Rome JJ, Rhodes JF Jr, Jones TK, Moskowitz WB, Holzer RJ, Zamora R. Pediatric catheterization laboratory anticoagulation with bivalirudin. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2011 Apr 1:77(5):671-9. doi: 10.1002/ccd.22817. Epub 2011 Jan 4
[PubMed PMID: 21433272]
[24]
Seelhammer TG, Bohman JK, Schulte PJ, Hanson AC, Aganga DO. Comparison of Bivalirudin Versus Heparin for Maintenance Systemic Anticoagulation During Adult and Pediatric Extracorporeal Membrane Oxygenation. Critical care medicine. 2021 Sep 1:49(9):1481-1492. doi: 10.1097/CCM.0000000000005033. Epub
[PubMed PMID: 33870916]
[25]
Li P, Zhang H, Luo C, Ji Z, Zheng Z, Li Z, Wu F, Li J, Hong L. Occurrence and Risk Factors of Adverse Drug Reactions in Patients Receiving Bivalirudin as Anticoagulant During Percutaneous Coronary Intervention: A Prospective, Multi-Center, Intensive Monitoring Study. Frontiers in cardiovascular medicine. 2021:8():781632. doi: 10.3389/fcvm.2021.781632. Epub 2022 Apr 29
[PubMed PMID: 35573935]
[26]
Latt H, Aung S, Kyaw K, Aung TT, Roongsritong C. A Case of Diffuse Alveolar Hemorrhage as a Possible Complication of Bivalirudin Therapy. The American journal of case reports. 2017 Oct 10:18():1081-1085
[PubMed PMID: 28993605]
Level 3 (low-level) evidence
[27]
Kuchulakanti PK, Satler LF, Rha SW, Waksman R. Bivalirudin-associated intracoronary thrombosis during gamma-brachytherapy and its experimental validation in acute swine model. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2004 Jun:62(2):209-13
[PubMed PMID: 15170713]
Level 1 (high-level) evidence
[28]
Caron MF, McKendall GR. Bivalirudin in percutaneous coronary intervention. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2003 Sep 15:60(18):1841-9
[PubMed PMID: 14521034]
[29]
Jiang XL, Yan X, Su HN, Liu YH, Han RX, Song ZY, Sun XW, Su DH, Yang X. [Analysis of management efficacy in patients with heavy menstrual bleeding associated with antithrombotic therapy]. Zhonghua fu chan ke za zhi. 2023 Apr 25:58(4):286-292. doi: 10.3760/cma.j.cn112141-20221130-00725. Epub
[PubMed PMID: 37072297]
[30]
Showkathali R, Natarajan A. Antiplatelet and antithrombin strategies in acute coronary syndrome: state-of-the-art review. Current cardiology reviews. 2012 Aug:8(3):239-49
[PubMed PMID: 22935021]
[31]
Zhong H, Zhu ML, Yu YT, Li W, Xing SP, Zhao XY, Wang WJ, Gu ZC, Gao Y. Management of Bivalirudin Anticoagulation Therapy for Extracorporeal Membrane Oxygenation in Heparin-Induced Thrombocytopenia: A Case Report and a Systematic Review. Frontiers in pharmacology. 2020:11():565013. doi: 10.3389/fphar.2020.565013. Epub 2020 Sep 11
[PubMed PMID: 33013402]
Level 1 (high-level) evidence
[32]
Helms J, Frere C, Thiele T, Tanaka KA, Neal MD, Steiner ME, Connors JM, Levy JH. Anticoagulation in adult patients supported with extracorporeal membrane oxygenation: guidance from the Scientific and Standardization Committees on Perioperative and Critical Care Haemostasis and Thrombosis of the International Society on Thrombosis and Haemostasis. Journal of thrombosis and haemostasis : JTH. 2023 Feb:21(2):373-396. doi: 10.1016/j.jtha.2022.11.014. Epub 2022 Dec 22
[PubMed PMID: 36700496]
[33]
Gleason TG, Chengelis CP, Jackson CB, Lindstrom P. A 24-hour continuous infusion study of bivalirudin in the rat. International journal of toxicology. 2003 May-Jun:22(3):195-206
[PubMed PMID: 12851152]
[34]
Buck ML. Bivalirudin as an Alternative to Heparin for Anticoagulation in Infants and Children. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG. 2015 Nov-Dec:20(6):408-17. doi: 10.5863/1551-6776-20.6.408. Epub
[PubMed PMID: 26766931]
[35]
Nagle EL, Dager WE, Duby JJ, Roberts AJ, Kenny LE, Murthy MS, Pretzlaff RK. Bivalirudin in pediatric patients maintained on extracorporeal life support. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. 2013 May:14(4):e182-8. doi: 10.1097/PCC.0b013e31827200b6. Epub
[PubMed PMID: 23648880]
[36]
White HD, Aylward PE, Frey MJ, Adgey AA, Nair R, Hillis WS, Shalev Y, Brown MA, French JK, Collins R, Maraganore J, Adelman B. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. Circulation. 1997 Oct 7:96(7):2155-61
[PubMed PMID: 9337184]
Level 1 (high-level) evidence